Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.

Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, Bansal N, Chon HS, Stickles XB, Kamath SG, Hakam A, Li L, Su D, Moreno C, Judson PL, Berchuck A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Bloom GC, Eschrich SA, Sebti S, Chen DT, Lancaster JM.

Clin Cancer Res. 2011 Oct 1;17(19):6356-66. doi: 10.1158/1078-0432.CCR-11-0735. Epub 2011 Aug 17.

2.

The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin.

Chon HS, Marchion DC, Xiong Y, Chen N, Bicaku E, Stickles XB, Bou Zgheib N, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Lancaster JM.

Gynecol Oncol. 2012 Jan;124(1):119-24. doi: 10.1016/j.ygyno.2011.09.020. Epub 2011 Oct 26.

PMID:
22032837
3.

The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer.

Bou Zgheib N, Xiong Y, Marchion DC, Bicaku E, Chon HS, Stickles XB, Sawah EA, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Cubitt CL, Chen DT, Lancaster JM.

Int J Oncol. 2012 Jul;41(1):179-88. doi: 10.3892/ijo.2012.1451. Epub 2012 Apr 26.

4.

BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin.

Bansal N, Marchion DC, Bicaku E, Xiong Y, Chen N, Stickles XB, Sawah EA, Wenham RM, Apte SM, Gonzalez-Bosquet J, Judson PL, Hakam A, Lancaster JM.

J Gynecol Oncol. 2012 Jan;23(1):35-42. doi: 10.3802/jgo.2012.23.1.35. Epub 2012 Jan 9.

5.

Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest.

Al Sawah E, Chen X, Marchion DC, Xiong Y, Ramirez IJ, Abbasi F, Bou Zgheib N, Chon HS, Wenham RM, Apte SM, Judson PL, Lancaster JM.

Gynecol Oncol. 2013 Oct;131(1):207-12. doi: 10.1016/j.ygyno.2013.07.088. Epub 2013 Jul 20.

PMID:
23877012
6.

In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival.

Bicaku E, Xiong Y, Marchion DC, Chon HS, Stickles XB, Chen N, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Fulp W, Cubitt CL, Chen DT, Lancaster JM.

Br J Cancer. 2012 Jun 5;106(12):1967-75. doi: 10.1038/bjc.2012.207. Epub 2012 May 17.

7.

Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance.

Boac BM, Xiong Y, Marchion DC, Abbasi F, Bush SH, Ramirez IJ, Khulpateea BR, Clair McClung E, Berry AL, Bou Zgheib N, Chon HS, Shahzad MM, Judson PL, Wenham RM, Apte SM, Berglund AE, Magliocco AM, Lancaster JM.

Gynecol Oncol. 2016 Feb;140(2):259-63. doi: 10.1016/j.ygyno.2015.12.026. Epub 2015 Dec 28.

8.

The Chinese herb polyphyllin D sensitizes ovarian cancer cells to cisplatin-induced growth arrest.

Al Sawah E, Marchion DC, Xiong Y, Ramirez IJ, Abbasi F, Boac BM, Bush SH, Bou Zgheib N, McClung EC, Khulpateea BR, Berry A, Hakam A, Wenham RM, Lancaster JM, Judson PL.

J Cancer Res Clin Oncol. 2015 Feb;141(2):237-42. doi: 10.1007/s00432-014-1797-x. Epub 2014 Aug 28.

PMID:
25164128
9.

BAD-mediated apoptotic pathway is associated with human cancer development.

Stickles XB, Marchion DC, Bicaku E, Al Sawah E, Abbasi F, Xiong Y, Bou Zgheib N, Boac BM, Orr BC, Judson PL, Berry A, Hakam A, Wenham RM, Apte SM, Berglund AE, Lancaster JM.

Int J Mol Med. 2015 Apr;35(4):1081-7. doi: 10.3892/ijmm.2015.2091. Epub 2015 Feb 5.

10.

Piceatannol enhances cisplatin sensitivity in ovarian cancer via modulation of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fission.

Farrand L, Byun S, Kim JY, Im-Aram A, Lee J, Lim S, Lee KW, Suh JY, Lee HJ, Tsang BK.

J Biol Chem. 2013 Aug 16;288(33):23740-50. doi: 10.1074/jbc.M113.487686. Epub 2013 Jul 5.

11.

Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.

Alkema NG, Tomar T, van der Zee AG, Everts M, Meersma GJ, Hollema H, de Jong S, van Vugt MA, Wisman GB.

Gynecol Oncol. 2014 Jun;133(3):591-8. doi: 10.1016/j.ygyno.2014.03.557. Epub 2014 Mar 20.

PMID:
24657486
12.

The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.

Ali AY, Abedini MR, Tsang BK.

Oncogene. 2012 Apr 26;31(17):2175-86. doi: 10.1038/onc.2011.399. Epub 2011 Sep 19.

PMID:
21927021
13.

PIM2 kinase is induced by cisplatin in ovarian cancer cells and limits drug efficacy.

Musiani D, Hammond DE, Cirillo L, Erriquez J, Olivero M, Clague MJ, Di Renzo MF.

J Proteome Res. 2014 Nov 7;13(11):4970-82. doi: 10.1021/pr500651n. Epub 2014 Aug 15.

PMID:
25099161
14.

A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.

Marchion DC, Bicaku E, Xiong Y, Bou Zgheib N, Al Sawah E, Stickles XB, Judson PL, Lopez AS, Cubitt CL, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund A, Lancaster JM.

Oncol Rep. 2013 May;29(5):2011-8. doi: 10.3892/or.2013.2329. Epub 2013 Mar 5.

15.

Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.

Mir R, Tortosa A, Martinez-Soler F, Vidal A, Condom E, Pérez-Perarnau A, Ruiz-Larroya T, Gil J, Giménez-Bonafé P.

Int J Cancer. 2013 Apr 1;132(7):1525-36. doi: 10.1002/ijc.27832. Epub 2012 Oct 11.

16.

Gene expression data reveal common pathways that characterize the unifocal nature of ovarian cancer.

Marchion DC, Xiong Y, Chon HS, Al Sawah E, Bou Zgheib N, Ramirez IJ, Abbasi F, Stickles XB, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund AE, Lancaster JM.

Am J Obstet Gynecol. 2013 Dec;209(6):576.e1-576.e16. doi: 10.1016/j.ajog.2013.08.004. Epub 2013 Aug 9.

17.

The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma.

Stronach EA, Cunnea P, Turner C, Guney T, Aiyappa R, Jeyapalan S, de Sousa CH, Browne A, Magdy N, Studd JB, Sriraksa R, Gabra H, El-Bahrawy M.

Oncotarget. 2015 Oct 13;6(31):31593-603. doi: 10.18632/oncotarget.3415.

18.

DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance.

Stronach EA, Chen M, Maginn EN, Agarwal R, Mills GB, Wasan H, Gabra H.

Neoplasia. 2011 Nov;13(11):1069-80.

19.

Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer.

Smith G, Ng MT, Shepherd L, Herrington CS, Gourley C, Ferguson MJ, Wolf CR.

Br J Cancer. 2012 Oct 9;107(8):1327-36. doi: 10.1038/bjc.2012.410. Epub 2012 Sep 18.

Supplemental Content

Support Center